WHO Programme for International Drug Monitoring
Generated by GPT-5-miniExpansion Funnel Raw 181 → Dedup 0 → NER 0 → Enqueued 0
| WHO Programme for International Drug Monitoring | |
|---|---|
| Name | WHO Programme for International Drug Monitoring |
| Formation | 1968 |
| Type | International health programme |
| Headquarters | Geneva, Switzerland |
| Parent organization | World Health Organization |
WHO Programme for International Drug Monitoring is a global pharmacovigilance initiative established to improve patient safety by monitoring adverse reactions to medicinal products. It connects national adverse drug reaction (ADR) centres, regulatory authorities, and international agencies to detect, assess, and prevent medicine-related harm. The programme supports signal detection, safety communication, and regulatory decision-making through collaborative databases and technical guidance.
History
The programme was created following concerns raised in the 1960s by Thalidomide-related disasters and subsequent regulatory reforms in United Kingdom, United States, Germany, and Sweden. In 1968 the World Health Organization convened member states and experts from United Kingdom MHRA, United States FDA, European Medicines Agency, CIOMS, and the International Drug Monitoring Programme to establish an international framework. Early contributors included the Netherlands', France, Denmark, Norway, and Finland pharmacovigilance centres, with pivotal collaborations from World Bank, UNICEF, and UNDP. Over decades the programme engaged stakeholders such as Institute of Medicine, Royal College of Physicians, European Commission, African Union, PAHO, CDC, and national agencies in India, China, Brazil, and Japan.
Structure and Governance
Governance involves partnerships among the World Health Organization Secretariat, the Uppsala Monitoring Centre, and national pharmacovigilance centres within member states like Canada Health, Health Canada, TGA (Australia), and MHRA. Advisory bodies have included representatives from World Health Assembly, WHO Executive Board, Bill & Melinda Gates Foundation, European Medicines Agency, and regional offices in Europe, Africa, Americas, South-East Asia, Eastern Mediterranean, and Western Pacific. The Uppsala Monitoring Centre, located in Uppsala, operates under agreements with Sweden and maintains operational links to institutions like Karolinska Institute and Uppsala University. Legal and policy interactions involve International Health Regulations, national statutes in France, Germany, Italy, and cooperation with agencies such as PMDA (Japan) and State Food and Drug Administration in China.
Pharmacovigilance Activities and Systems
The programme promotes activities including spontaneous reporting, active surveillance, cohort event monitoring, and signal management used by organisations such as European Medicines Agency, Food and Drug Administration, Health Canada, TGA, PMDA, ANVISA (Brazil), and Medicines Control Council in South Africa. It issues guidelines aligned with CIOMS reports, International Conference on Harmonisation (ICH) requirements, and Good Pharmacovigilance Practices used by Novartis, Pfizer, Roche, GlaxoSmithKline, AstraZeneca, Sanofi, Johnson & Johnson, and Bayer. Training and capacity building have involved partnerships with London School of Hygiene & Tropical Medicine, University of Oxford, Harvard University, Johns Hopkins University, Makerere University, AIIMS, and University of Cape Town. Collaborative programmes include work with GAVI, Global Fund, UNICEF, and Médecins Sans Frontières on vaccine and treatment safety.
Membership and Participating Countries
Membership comprises national pharmacovigilance centres from over 150 countries, including founding and longstanding participants such as United Kingdom, United States, Sweden, Norway, Netherlands, France, Germany, Italy, Spain, Japan, China, India, Brazil, South Africa, Australia, Canada, Argentina, Mexico, Egypt, Nigeria, Kenya, Ethiopia, Pakistan, Bangladesh, Thailand, Indonesia, Philippines, Vietnam, Malaysia, New Zealand, Switzerland, Belgium, Poland, Czech Republic, Austria, Greece, Portugal, Ireland, Finland, Denmark, Iceland, Lithuania, Latvia, Estonia, Slovakia, Slovenia, Croatia, Romania, Bulgaria, Hungary, Serbia, Ukraine, Belarus, Russia, Kazakhstan, Uzbekistan, Israel, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman, Lebanon, Jordan, Morocco, Tunisia, Algeria, Senegal, Ghana, Cameroon, Ivory Coast, Zambia, Zimbabwe, Mozambique', Angola, Tanzania, Uganda, and others across Caribbean and Pacific Islands.
Data Collection and VigiBase
Central to the programme is VigiBase, managed by the Uppsala Monitoring Centre in Uppsala, which aggregates individual case safety reports (ICSRs) from national centres in MedDRA-coded format compatible with ICH standards and the WHO Drug Dictionary. VigiBase supports signal detection methodologies used by European Medicines Agency, United States FDA, Health Canada, PHARMAC (New Zealand), and academic groups at Harvard School of Public Health, University of Liverpool, Uppsala University, and University of Copenhagen. Data sharing arrangements respect national laws such as those in European Union member states under the GDPR and involve collaborations with World Bank, OECD, UNICEF, and research consortia including IMI projects. Analytical tools used with VigiBase include disproportionality algorithms, Bayesian methods, and data mining techniques applied in partnership with institutions like Karolinska Institutet and companies such as Oracle and IBM.
Key Achievements and Impact
The programme has contributed to major regulatory actions and public health responses, including international alerts involving Thalidomide, safety communications on Rofecoxib, guidance influencing labeling changes for Isotretinoin, detection of signals related to HIV antiretroviral therapies, and vaccine safety monitoring for Measles/Rubella and Polio campaigns coordinated with WHO regional offices and PAHO. It has supported pharmacovigilance strengthening in low- and middle-income countries through partnerships with GAVI and Global Fund, influenced clinical guidelines from World Health Organization expert committees, and facilitated post-marketing surveillance for products from GlaxoSmithKline, Merck, Sanofi, and Pfizer.
Challenges and Future Directions
Ongoing challenges include underreporting in resource-limited settings such as parts of Sub-Saharan Africa and South Asia, interoperability with national electronic health records in United Kingdom, United States, India, and China, and harmonizing standards across regulatory systems like European Medicines Agency, FDA, and PMDA. Future directions emphasize integration with real-world data sources from hospitals, insurance databases like those used in United States Medicare, active surveillance projects at Kaiser Permanente, enhanced collaboration with pharmaceutical industry partners, and application of artificial intelligence developed by academic centres such as Massachusetts Institute of Technology, Stanford University, and ETH Zurich. Strengthening legal frameworks, training via universities including Imperial College London and University of Toronto, and expanded regional hubs in Africa and Asia aim to improve global medicine safety surveillance.